Validation of Modified Albumin‐Bilirubin‐Tumor Stage as a Prognostic Model in Early‐Stage Hepatocellular Carcinoma Treated With Radiofrequency Ablation
The Kaohsiung Journal of Medical Sciences · 02.11.2026
DOI: 10.1002/kjm2.70313 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, online erschienen am 02.11.2026. Verfasst von Cheng-Ying Hsieh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Med…. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Survival after radiofrequency ablation (RFA) for very early‐ or early‐stage hepatocellular carcinoma (HCC) remains heterogeneous because prognosis depends on both tumor burden and hepatic reserve. We retrospectively evaluated treatment‐naive patients with Barcelona Clinic Liver Cancer (BCLC) Stages 0 or A HCC treated with RFA as initial therapy from January 2002 to September 2016. Patients with Child‐Pugh class A or B and complete ablation were included. Four prespecified total scores, Child‐Pugh‐tumor (CP‐T), albumin‐bilirubin‐tumor (ALBI‐T), modified ALBI‐tumor (mALBI‐T), and platelet‐ALBI‐tumor (pALBI‐T) were compared using the Akaike information criterion (AIC), Harrell concordance index (C‐index), time‐dependent area under the receiver operating characteristic curve, calibration, and subgroup analyses. Of 1238 patients screened, 950 were included; 831 (87.5%) were Child‐Pugh class A. During a median follow‐up of 5.44 years, 417 deaths occurred; 5‐ and 10‐year overall survival rates were 58.0% and 35.8%, respectively. The American Joint Committee on Cancer eighth‐edition T stage illustrated the best tumor‐stage performance and was used in the total scores, while mALBI‐T had the lowest AIC (5052.2) and highest Harrell C‐index (0.628; 95% confidence interval, 0.601–0.655). Paired bootstrap differences versus CP‐T, ALBI‐T, and pALBI‐T were statistically significant, but modest, while mALBI‐T performed best at 5 years and in Child‐Pugh class A patients, whereas all models showed limited discrimination in Child‐Pugh class B patients. Apparent calibration was generally close, and mALBI‐T also had the best fit for recurrence‐free survival. mALBI‐T provides a simple prognostic model for long‐term survival stratification after complete ablation in early‐stage hepatocellular carcinoma, especially in Child‐Pugh class A patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung City, Taiwan.
- Division of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung City, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jen-Ai Hospital, Taichung City, Taiwan.
ORCID-Profile: Yi-Hao Yen, Yuan-Hung Kuo, Ming-Chao Tsai, Sheng-Nan Lu, Chao-Hung Hung, Jing-Houng Wang, Chien-Hung Chen, Kwong-Ming Kee
Zitieren
APA
Hsieh, C. Y., Yeh, W. S., Yen, Y. H., Kuo, Y. H., Tsai, M. C., Lu, S. N., Hung, C. H., Wang, J. H., Chen, C. H., & Kee, K. M. (2026). Validation of Modified Albumin‐Bilirubin‐Tumor Stage as a Prognostic Model in Early‐Stage Hepatocellular Carcinoma Treated With Radiofrequency Ablation. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70313
Vancouver
Hsieh CY, Yeh WS, Yen YH, Kuo YH, Tsai MC, Lu SN, et al. Validation of Modified Albumin‐Bilirubin‐Tumor Stage as a Prognostic Model in Early‐Stage Hepatocellular Carcinoma Treated With Radiofrequency Ablation. The Kaohsiung Journal of Medical Sciences. 2026. doi:10.1002/kjm2.70313
BibTeX
@article{Hsieh2026,
author = {Hsieh, Cheng-Ying and Yeh, Wen-Shuo and Yen, Yi-Hao and Kuo, Yuan-Hung and Tsai, Ming-Chao and Lu, Sheng-Nan and Hung, Chao-Hung and Wang, Jing-Houng and Chen, Chien-Hung and Kee, Kwong-Ming},
title = {Validation of Modified Albumin‐Bilirubin‐Tumor Stage as a Prognostic Model in Early‐Stage Hepatocellular Carcinoma Treated With Radiofrequency Ablation},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2026},
doi = {10.1002/kjm2.70313}
}
EUVIMED